ペン型注入器市場

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2021年11月

ペン型注入器市場:製品タイプ(使い捨て、再利用可能なペン)、治療[糖尿病(インスリン、GLP-1)、成長ホルモン、骨粗鬆症、生殖能力、自己免疫疾患、がん)、エンドユーザー(病院、診療所、在宅医療)、地域別 – 2026年までの世界予測

Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region – Global Forecast to 2026

ページ数 225
図表数 239
種別 英文調査報告書

目次  お問合せ

The global injection pens market is projected to reach USD 53.3 billion by 2026 from USD 37.6 billion in 2021, at a CAGR of 7.2% during the forecast period. Growing prevalence of chronic diseases, increasing number of regulatory approvals, favourable reimbursement and government support, and technological advancements in injection pens tend to drive the market. Though the market is growing, but factors like alternative drug delivery modes, poor reimbursement scenarios in developing regions and needle anxiety tend to restrain the market growth. Whereas, needle-stick injuries & misuse of injection pens tend to pose a challenge for the market. But, the opportunities for the market lie in the patent expiry of biologics and emerging markets.

Based on product, the disposable injection pen segment holds the largest share during the forecast period.
Based on type, the injection pens market is segmented into reusable and disposable injection pens. In 2020, the disposable injection pens segment accounted for the largest share of the global injection pens market. The large share of the disposable injection pens segment can be attributed to their ease of use and the presence of a built-in cartridge which eliminates the need for manually loading the cartridge, making it more convenient for patients with reduced dexterity or visual impairments.

Based on therapy, the diabetes segment holds the highest growth rate during the forecast period.
Based on therapy, the injection pens market is segmented into diabetes, growth hormone therapy, fertility, osteoporosis, autoimmune diseases, cancer, and other therapies. In 2020, the diabetes segment accounted for the largest share of the injection pens market. The large share of this segment is attributed to the high prevalence of diabetes, increasing awareness about insulin pens among diabetic patients, the rising geriatric population, increased patient support programs by companies & government for diabetes, and the growing availability of insulin pens in the market.

Based on diabetes therapy, the in GLP-1 segment holds the highest growth rate during the forecast period.
Based on type of diabetes therapy, the injection pens market for diabetes therapy is segmented into insulin and GLP-1. In 2020, the GLP-1 segment accounted for the highest growth rate of the injection pens market for diabetes therapy. The growth in the market can be attributed to the higher efficiency of GLP-1 to reduce the blood sugar levels.

Based on end user, the home-care settings segment holds the highest growth rate during the forecast period.
Based on end users, the injection pens market is segmented into home care settings and hospitals & clinics. In 2020, the home care settings segment accounted for the highest growth of the injection pens market. The growing geriatric population, ease of drug administration, increasing prevalence of chronic diseases, technological advancements, and favorable reimbursement scenarios are some of the key factors driving the growth rate of the home care settings market.

Asia Pacific is expected to grow at the highest rate in 2020
Asia Pacific is expected to grow at the highest rate in the forecast year. The rising geriatric population, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for advanced technologies, and expansion of private-sector hospitals to rural areas in various countries in the APAC are the major factors driving the growth of the injection pen market in this region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–60%, Tier 2–30%, and Tier 3–10%
• By Designation – C-level–30%, Director-level–50%, Others–20%
• By Region – North America–45%, Europe–15%, Asia Pacific–25%, Latin America- 10%, Middle East and Africa–5%

Key players in the Injection pen market

Prominent players in the injection pens market include Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), Novartis AG (Switzerland), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK), Sulzer Ltd. (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Pfizer (US), Biocon Ltd. (India), Lupin Ltd. (India), Wockhardt Ltd. (India), AptarGroup, Inc. (US), and Gerresheimer AG (Germany). The other players includes Shaily Engineering Plastics Ltd. (India), Bespak Europe Ltd. (UK), SHL Medical AG (Switzerland), Emperra GmbH (Germany), Nemera France SAS, Companion Medical, Inc. (US), and Jiangsu Delfu Medical Device Co., Ltd. (China).

Research Coverage:
The report analyzes the injection pen market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, therapy, end user, and region. The report also includes a product portfolio matrix of various injection pen products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global injection pen market. The report analyzes this market by product type, therapy, end user and region
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global injection pen market
• Market Development: Comprehensive information on the lucrative emerging markets by product type, therapy, end user and region
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global injection pen market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global injection pen market.


目次

1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED FOR THE STUDY 29
1.3.3 CURRENCY 29
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 29
1.4 STAKEHOLDERS 30
1.5 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 34
FIGURE 2 PRIMARY SOURCES 34
2.1.2.1 Key data from primary sources 35
2.1.2.2 Key industry insights 36
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 36
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 37
2.2 MARKET SIZE ESTIMATION 37
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 38
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: SANOFI 38
FIGURE 7 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES:
INJECTION PENS MARKET (2020) 39
FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTION
PENS MARKET (2021–2026) 40
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 10 TOP-DOWN APPROACH 41
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 42
FIGURE 11 MARKET DATA TRIANGULATION METHODOLOGY 42
2.4 MARKET SHARE ANALYSIS 43
2.5 ASSUMPTIONS FOR THE STUDY 43

2.6 RISK ASSESSMENT 43
TABLE 2 RISK ASSESSMENT: INJECTION PENS MARKET 43
2.7 LIMITATIONS 44
2.7.1 METHODOLOGY-RELATED LIMITATIONS 44
2.7.2 SCOPE-RELATED LIMITATIONS 44
3 EXECUTIVE SUMMARY 45
FIGURE 12 INJECTION PENS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 45
FIGURE 13 INJECTION PENS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION) 46
FIGURE 14 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2021 VS. 2026 (USD MILLION) 46
FIGURE 15 INJECTION PENS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 47
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE INJECTION PENS MARKET 48
4 PREMIUM INSIGHTS 49
4.1 INJECTION PENS MARKET OVERVIEW 49
FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 49
4.2 ASIA PACIFIC: INJECTION PENS MARKET, BY THERAPY AND COUNTRY (2020) 50
FIGURE 18 DIABETES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC INJECTION PENS MARKET IN 2020 50
4.3 INJECTION PENS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE INJECTION PENS MARKET DURING THE FORECAST PERIOD 51
4.4 INJECTION PENS MARKET, BY REGION, 2021–2026 52
FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL
INJECTION PENS MARKET IN 2026 52
4.5 INJECTION PENS MARKET: DEVELOPED VS. DEVELOPING MARKETS 52
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 MARKET DYNAMICS 53
FIGURE 22 INJECTION PENS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 53
5.1.1 MARKET DRIVERS 54
5.1.1.1 Growing prevalence of chronic diseases 54
FIGURE 23 NUMBER OF PEOPLE WITH CHRONIC DISEASES IN THE US,
1995–2030 (MILLION INDIVIDUALS) 54
FIGURE 24 ESTIMATED DIABETIC POPULATION, BY REGION,
2019 VS. 2030 VS. 2040 (MILLION) 55
FIGURE 25 GLOBAL CANCER INCIDENCE, 2015–2040 (MILLION) 55
5.1.1.2 Increasing number of regulatory approvals 55
5.1.1.3 Favorable reimbursement and government support 56
5.1.1.4 Technological advancements in injection pens 56
TABLE 3 MARKET DRIVERS: IMPACT ANALYSIS 57
5.1.2 MARKET RESTRAINTS 57
5.1.2.1 Preference for alternative drug delivery modes 57
5.1.2.2 Poor reimbursement scenario in developing countries 57
5.1.2.3 Needle anxiety 57
TABLE 4 MARKET RESTRAINTS: IMPACT ANALYSIS 58
5.1.3 MARKET OPPORTUNITIES 58
5.1.3.1 Patent expiry of biologics to drive the demand for biosimilars 58
5.1.3.2 Growth opportunities in emerging markets 58
FIGURE 26 DIABETES POPULATION IN DEVELOPING COUNTRIES,
2020 VS. 2040 (MILLION) 59
TABLE 5 RISING INCOME LEVELS IN EMERGING COUNTRIES 59
TABLE 6 MARKET OPPORTUNITIES: IMPACT ANALYSIS 60
5.1.4 MARKET CHALLENGES 60
5.1.4.1 Needlestick injuries and misuse of injection pens 60
TABLE 7 MARKET CHALLENGES: IMPACT ANALYSIS 61
5.2 VALUE CHAIN ANALYSIS 61
FIGURE 27 INJECTION PENS MARKET: VALUE CHAIN ANALYSIS 61
5.3 SUPPLY CHAIN ANALYSIS 62
FIGURE 28 INJECTION PENS MARKET: SUPPLY CHAIN ANALYSIS 63
5.4 PRICING ANALYSIS 63
TABLE 8 PRICING OF INJECTION PENS AVAILABLE IN THE MARKET 64
5.5 ECOSYSTEM MARKET MAP 65
FIGURE 29 INJECTION PENS MARKET: ECOSYSTEM MARKET MAP 65
5.6 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 9 INJECTION PENS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.6.1 INTENSITY OF COMPETITIVE RIVALRY 66
5.6.2 BARGAINING POWER OF SUPPLIERS 66
5.6.3 BARGAINING POWER OF BUYERS 66
5.6.4 THREAT OF SUBSTITUTES 66
5.6.5 THREAT OF NEW ENTRANTS 67
5.7 REGULATORY ANALYSIS 67
5.7.1 NORTH AMERICA 67
5.7.1.1 US 67
TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 67
TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 68
5.7.1.2 Canada 68
TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 68
FIGURE 30 CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS 69
5.7.2 EUROPE 69
FIGURE 31 EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES 69
5.7.3 ASIA PACIFIC 70
5.7.3.1 Japan 70
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 70
5.7.3.2 China 71
TABLE 14 CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL 71
TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES 71
5.7.3.3 India 71
5.8 IMPACT OF COVID-19 ON THE INJECTION PENS MARKET 72
5.9 PATENT ANALYSIS 72
5.9.1 PATENT PUBLICATION TRENDS FOR INJECTION PENS 72
FIGURE 32 PATENT PUBLICATION TRENDS (JANUARY 2011–SEPTEMBER 2021) 73
5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 73
FIGURE 33 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR
INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021) 74
FIGURE 34 TOP APPLICANT COUNTRIES/REGIONS FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021) 75
5.10 TECHNOLOGY ANALYSIS 75
TABLE 16 PEN INJECTORS CLASSIFICATION 75
5.10.1 KEY TECHNOLOGIES 76
5.10.1.1 Dose setting and needle actuation 76
5.10.1.2 Pen injector material 76
5.10.2 COMPLEMENTARY TECHNOLOGIES 76
5.10.2.1 In-built dose and time log 76
5.10.2.2 Wireless connectivity 76
5.10.2.3 Smartpen injectors 77
5.10.2.4 Smart caps and attachments 77
5.10.2.5 Injector temperature monitoring 77
5.10.3 ADJACENT TECHNOLOGIES 78
5.10.3.1 Autoinjectors 78
5.10.3.2 Insulin pumps 78
6 INJECTION PENS MARKET, BY TYPE 79
6.1 INTRODUCTION 80
TABLE 17 INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 80
6.2 DISPOSABLE INJECTION PENS 80
6.2.1 HIGH PATIENT COMPLIANCE AND EASE OF HANDLING TO DRIVE
THE ADOPTION OF DISPOSABLE INJECTION PENS 80
TABLE 18 DISPOSABLE INJECTION PENS AVAILABLE IN THE MARKET 81
TABLE 19 DISPOSABLE INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 81
6.3 REUSABLE INJECTION PENS 82
6.3.1 REUSABLE INJECTION PENS TO REGISTER THE HIGHEST GROWTH
DUE TO TECHNOLOGICAL ADVANCEMENTS 82
TABLE 20 REUSABLE INJECTION PENS AVAILABLE IN THE MARKET 82
TABLE 21 REUSABLE INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 83
7 INJECTION PENS MARKET, BY THERAPY 84
7.1 INTRODUCTION 85
TABLE 22 INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 85
7.2 DIABETES 85
TABLE 23 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 86
TABLE 24 INJECTION PENS MARKET FOR DIABETES THERAPY, BY COUNTRY,
2019–2026 (USD MILLION) 86
7.2.1 INSULIN 87
7.2.1.1 Rising prevalence of diabetes is driving the growth of this market 87
TABLE 25 EXAMPLES OF INSULIN INJECTION PENS 88
TABLE 26 INJECTION PENS MARKET FOR INSULIN THERAPY, BY COUNTRY,
2019–2026 (USD MILLION) 88
7.2.2 GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY 89
7.2.2.1 Strong focus of major pharmaceutical companies to introduce
GLP-1 drugs to drive market growth 89
TABLE 27 EXAMPLES OF GLP-1 INJECTION PENS 89
TABLE 28 INJECTION PENS MARKET FOR GLP-1 THERAPY, BY COUNTRY,
2019–2026 (USD MILLION) 90
7.3 GROWTH HORMONE THERAPY 90
7.3.1 DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN
THE MARKET GROWTH 90
TABLE 29 EXAMPLES OF INJECTION PENS FOR GROWTH HORMONE THERAPY 91
TABLE 30 INJECTION PENS MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 92
7.4 OSTEOPOROSIS 92
7.4.1 GROWING PREVALENCE OF OSTEOPOROSIS IN GERIATRIC PATIENTS AND WOMEN TO DRIVE MARKET GROWTH 92
TABLE 31 EXAMPLES OF INJECTION PENS FOR OSTEOPOROSIS THERAPY 93
TABLE 32 INJECTION PENS MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 94
7.5 FERTILITY 94
7.5.1 DECREASE IN FERTILITY RATE HAS RESULTED IN THE INCREASED
USE OF INJECTION PENS 94
TABLE 33 EXAMPLES OF INJECTION PENS FOR FERTILITY THERAPY 95
TABLE 34 INJECTION PENS MARKET FOR FERTILITY THERAPY, BY COUNTRY,
2019–2026 (USD MILLION) 95
7.6 CANCER 96
7.6.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 96
TABLE 35 EXAMPLES OF INJECTION PENS FOR CANCER THERAPY 96
TABLE 36 INJECTION PENS MARKET FOR CANCER THERAPY, BY COUNTRY,
2019–2026 (USD MILLION) 97
7.7 AUTOIMMUNE DISEASES 97
7.7.1 DEVELOPMENTS IN THERAPIES AND DELIVERY DEVICES FOR THE TREATMENT OF MS TO BOOST THE MARKET GROWTH 97
TABLE 37 EXAMPLES OF INJECTION PENS FOR MULTIPLE SCLEROSIS AND
PSORIASIS THERAPY 98
TABLE 38 INJECTION PENS MARKET FOR AUTOIMMUNE DISEASE THERAPY,
BY COUNTRY, 2019–2026 (USD MILLION) 98
7.8 OTHER THERAPIES 99
TABLE 39 INJECTION PENS MARKET FOR OTHER THERAPIES, BY COUNTRY,
2019–2026 (USD MILLION) 99
8 INJECTION PENS MARKET, BY END USER 100
8.1 INTRODUCTION 101
TABLE 40 INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 101
8.2 HOME CARE SETTINGS 101
8.2.1 HOME CARE SETTINGS ARE THE LARGEST END USERS OF INJECTION PENS 101
TABLE 41 INJECTION PENS MARKET FOR HOME CARE SETTINGS, BY COUNTRY,
2019–2026 (USD MILLION) 102
8.3 HOSPITALS & CLINICS 103
8.3.1 GROWING INCIDENCE OF NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES HAVE INCREASED THE DEMAND FOR INJECTION PENS 103
TABLE 42 INJECTION PENS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,
2019–2026 (USD MILLION) 104
9 INJECTION PENS MARKET, BY REGION 105
9.1 INTRODUCTION 106
TABLE 43 INJECTION PENS MARKET, BY REGION, 2019–2026 (USD MILLION) 106
FIGURE 35 EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH
IN THE FORECAST PERIOD 107
9.2 NORTH AMERICA 107
FIGURE 36 NORTH AMERICA: INJECTION PENS MARKET SNAPSHOT 108
TABLE 44 INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 45 NORTH AMERICA: INJECTION PENS MARKET, BY TYPE,
2019–2026 (USD MILLION) 109
TABLE 46 NORTH AMERICA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 109
TABLE 47 NORTH AMERICA: INJECTION PENS MARKET FOR DIABETES THERAPY,
BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 48 NORTH AMERICA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 110
9.2.1 US 110
9.2.1.1 The US dominates the North American injection pens market 110
FIGURE 37 TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020) 110
TABLE 49 US: KEY MACROINDICATORS 111
TABLE 50 US: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 112
TABLE 51 US: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 112
TABLE 52 US: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 112
TABLE 53 US: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 113
9.2.2 CANADA 113
9.2.2.1 Unfavorable regulatory processes in Canada to restrain
the market growth 113
TABLE 54 CANADA: KEY MACROINDICATORS 114
TABLE 55 CANADA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 114
TABLE 56 CANADA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 115
TABLE 57 CANADA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 115
TABLE 58 CANADA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 115
9.3 EUROPE 116
TABLE 59 EUROPE: INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 116
TABLE 60 EUROPE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 61 EUROPE: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 117
TABLE 62 EUROPE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 117
TABLE 63 EUROPE: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 118
9.3.1 GERMANY 118
9.3.1.1 High diabetes expenditure and reimbursement for injection pens to drive the market in Germany 118
TABLE 64 GERMANY: KEY MACROINDICATORS 119
TABLE 65 GERMANY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 119
TABLE 66 GERMANY: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 120
TABLE 67 GERMANY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 120
TABLE 68 GERMANY: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 120
9.3.2 FRANCE 121
9.3.2.1 Misuse of injection pens pose a threat to the growth of this market 121
TABLE 69 FRANCE: KEY MACROINDICATORS 121
TABLE 70 FRANCE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 122
TABLE 71 FRANCE: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 122
TABLE 72 FRANCE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 122
TABLE 73 FRANCE: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 123
9.3.3 UK 123
9.3.3.1 NHS support and access to cost-effective injection pens are likely to drive the market in the UK 123
TABLE 74 UK: KEY MACROINDICATORS 124
TABLE 75 UK: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 124
TABLE 76 UK: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 125
TABLE 77 UK: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 125
TABLE 78 UK: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 125
9.3.4 ITALY 126
9.3.4.1 Regional variation in terms of coverage and benefits to hinder the market growth 126
TABLE 79 ITALY: KEY MACROINDICATORS 126
TABLE 80 ITALY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 127
TABLE 81 ITALY: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 127
TABLE 82 ITALY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 127
TABLE 83 ITALY: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 128
9.3.5 SPAIN 128
9.3.5.1 Supportive regulations mandating the use of safety injection pens to boost the growth of the Spanish market 128
TABLE 84 SPAIN: KEY MACROINDICATORS 129
TABLE 85 SPAIN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 86 SPAIN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 130
TABLE 87 SPAIN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 88 SPAIN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 130
9.3.6 BENELUX 131
9.3.6.1 Increasing awareness about injection pen devices to
drive market growth 131
TABLE 89 BENELUX: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 131
TABLE 90 BENELUX: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 132
TABLE 91 BENELUX: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 92 BENELUX: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 132
9.3.7 REST OF EUROPE 133
TABLE 93 ROE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 133
TABLE 94 ROE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 134
TABLE 95 ROE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 134
TABLE 96 ROE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 134
9.4 ASIA PACIFIC 135
FIGURE 38 ASIA PACIFIC: INJECTION PENS MARKET SNAPSHOT 136
TABLE 97 APAC: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 137
TABLE 98 APAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 99 APAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 137
TABLE 100 APAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 101 APAC: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 138
9.4.1 JAPAN 138
9.4.1.1 High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan 138
TABLE 102 JAPAN: KEY MACROINDICATORS 139
TABLE 103 JAPAN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 139
TABLE 104 JAPAN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 140
TABLE 105 JAPAN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 140
TABLE 106 JAPAN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 140
9.4.2 CHINA 141
9.4.2.1 Large patient population and healthcare infrastructure improvements to drive the market growth in China 141
TABLE 107 CHINA: KEY MACROINDICATORS 141
TABLE 108 CHINA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 142
TABLE 109 CHINA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 142
TABLE 110 CHINA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 142
TABLE 111 CHINA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 143
9.4.3 INDIA 143
9.4.3.1 Rising prevalence of obesity to drive market growth 143
TABLE 112 INDIA: KEY MACROINDICATORS 144
TABLE 113 INDIA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 114 INDIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 145
TABLE 115 INDIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 145
TABLE 116 INDIA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 145
9.4.4 SOUTHEAST ASIA 146
9.4.4.1 Growing awareness about diabetes to drive the adoption of
injection pens 146
FIGURE 39 DIABETES PREVALENCE IN SOUTHEAST ASIA (2019) 146
FIGURE 40 HEALTHCARE EXPENDITURE (% OF GDP) IN SOUTHEAST ASIA (2018) 147
FIGURE 41 GERIATRIC POPULATION (% OF THE TOTAL POPULATION), 2019 147
TABLE 117 SOUTHEAST ASIA: INJECTION PENS MARKET, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 118 SOUTHEAST ASIA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 148
TABLE 119 SOUTHEAST ASIA: INJECTION PENS MARKET FOR DIABETES THERAPY,
BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 120 SOUTHEAST ASIA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 148
9.4.5 REST OF APAC 149
TABLE 121 ROAPAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 149
TABLE 122 ROAPAC: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 149
TABLE 123 ROAPAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 150
TABLE 124 ROAPAC: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 150
9.5 LATIN AMERICA 150
TABLE 125 LATAM: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 151
TABLE 126 LATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 127 LATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 151
TABLE 128 LATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 152
TABLE 129 LATAM: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 152
9.5.1 BRAZIL 152
9.5.1.1 Brazil dominates the injection pens market in Latin America 152
TABLE 130 BRAZIL: KEY MACROINDICATORS 153
TABLE 131 BRAZIL: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 153
TABLE 132 BRAZIL: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 154
TABLE 133 BRAZIL: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 134 BRAZIL: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 154
9.5.2 MEXICO 155
9.5.2.1 Increasing incidence of lifestyle-related disorders to drive
market growth in Mexico 155
TABLE 135 MEXICO: KEY MACROINDICATORS 155
TABLE 136 MEXICO: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 156
TABLE 137 MEXICO: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 156
TABLE 138 MEXICO: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 156
TABLE 139 MEXICO: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 157
9.5.3 REST OF LATIN AMERICA 157
FIGURE 42 HEALTH EXPENDITURE (% OF GDP) IN LATIN AMERICAN COUNTRIES, 2018 157
TABLE 140 ROLATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 141 ROLATAM: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION) 158
TABLE 142 ROLATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 143 ROLATAM: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION) 159
9.6 MIDDLE EAST & AFRICA 159
9.6.1 INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY TO
SUPPORT MARKET GROWTH 159
TABLE 144 MEA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 145 MEA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 160
TABLE 146 MEA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION) 160
TABLE 147 MEA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 161
10 COMPETITIVE LANDSCAPE 162
10.1 OVERVIEW 162
10.2 KEY PLAYER STRATEGIES 162
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 163
FIGURE 43 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE INJECTION PENS MARKET 163
10.4 MARKET SHARE ANALYSIS 164
FIGURE 44 INJECTION PENS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 164
10.5 MARKET RANKING ANALYSIS OF OEM COMPANIES 165
FIGURE 45 INJECTION PENS MARKET RANKING, BY OEM COMPANY (2020) 165
10.6 COMPANY EVALUATION QUADRANT 166
10.6.1 STARS 166
10.6.2 EMERGING LEADERS 166
10.6.3 PERVASIVE PLAYERS 166
10.6.4 PARTICIPANTS 166
FIGURE 46 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT (2020) 167
10.7 COMPANY EVALUATION QUADRANT FOR START-UPS 168
10.7.1 PROGRESSIVE COMPANIES 168
10.7.2 DYNAMIC COMPANIES 168
10.7.3 STARTING BLOCKS 168
10.7.4 RESPONSIVE COMPANIES 168
FIGURE 47 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS (2020) 169
10.8 COMPANY PRODUCT FOOTPRINT 170
TABLE 148 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY TYPE 170
TABLE 149 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY THERAPY 171
10.9 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE INJECTION PENS MARKET 173
TABLE 150 GEOGRAPHIC REVENUE MIX: INJECTION PENS MARKET (2020) 173
10.10 COMPETITIVE SCENARIO 174
10.10.1 PRODUCT LAUNCHES 174
TABLE 151 PRODUCT LAUNCHES (JANUARY 2018–SEPTEMBER 2021) 174
10.10.2 OTHER DEVELOPMENTS 175
TABLE 152 OTHER DEVELOPMENTS (JANUARY 2018–SEPTEMBER 2021) 175

11 COMPANY PROFILES 176
11.1 KEY PLAYERS 176
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1.1 NOVO NORDISK A/S 176
TABLE 153 NOVO NORDISK A/S: BUSINESS OVERVIEW 176
FIGURE 48 NOVO NORDISK A/S: COMPANY SNAPSHOT (2020) 177
11.1.2 BECTON, DICKINSON AND COMPANY 179
TABLE 154 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 179
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 180
11.1.3 YPSOMED HOLDING AG 182
TABLE 155 YPSOMED HOLDING AG: BUSINESS OVERVIEW 182
FIGURE 50 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020) 183
11.1.4 SANOFI 185
TABLE 156 SANOFI: BUSINESS OVERVIEW 185
FIGURE 51 SANOFI: COMPANY SNAPSHOT (2020) 186
11.1.5 ELI LILLY AND COMPANY 188
TABLE 157 ELI LILLY AND COMPANY: BUSINESS OVERVIEW 188
FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020) 189
11.1.6 MERCK KGAA 191
TABLE 158 MERCK KGAA: BUSINESS OVERVIEW 191
FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT (2020) 192
11.1.7 ASTRAZENECA 193
TABLE 159 ASTRAZENECA: BUSINESS OVERVIEW 193
FIGURE 54 ASTRAZENECA: COMPANY SNAPSHOT (2020) 194
11.1.8 F. HOFFMANN-LA ROCHE LTD. 196
TABLE 160 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 196
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 197
11.1.9 OWEN MUMFORD 198
TABLE 161 OWEN MUMFORD: BUSINESS OVERVIEW 198
11.1.10 SULZER LTD. 199
TABLE 162 SULZER LTD.: BUSINESS OVERVIEW 199
11.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD. 200
TABLE 163 SUN PHARMACEUTICAL INDUSTRIES LTD: BUSINESS OVERVIEW 200
FIGURE 56 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020) 201
11.1.12 PFIZER 202
TABLE 164 PFIZER: BUSINESS OVERVIEW 202
FIGURE 57 PFIZER: COMPANY SNAPSHOT (2020) 203
11.1.13 BIOCON LTD. 204
TABLE 165 BIOCON LTD.: BUSINESS OVERVIEW 204
FIGURE 58 BIOCON LTD.: COMPANY SNAPSHOT (2020) 205

11.1.14 LUPIN LTD. 206
TABLE 166 LUPIN LTD.: BUSINESS OVERVIEW 206
FIGURE 59 LUPIN LTD.: COMPANY SNAPSHOT (2020) 207
11.1.15 WOCKHARDT LTD. 208
TABLE 167 WOCKHARDT LTD.: BUSINESS OVERVIEW 208
FIGURE 60 WOCKHARDT LTD.: COMPANY SNAPSHOT (2020) 208
11.1.16 APTARGROUP, INC. 210
TABLE 168 APTARGROUP, INC.: BUSINESS OVERVIEW 210
FIGURE 61 APTARGROUP, INC.: COMPANY SNAPSHOT (2020) 211
11.1.17 NOVARTIS AG 212
TABLE 169 NOVARTIS AG: BUSINESS OVERVIEW 212
FIGURE 62 NOVARTIS AG: COMPANY SNAPSHOT (2020) 213
11.1.18 GERRESHEIMER AG 214
TABLE 170 GERRESHEIMER AG: BUSINESS OVERVIEW 214
FIGURE 63 GERRESHEIMER AG: COMPANY SNAPSHOT (2020) 215
11.2 OTHER PLAYERS 216
11.2.1 SHAILY ENGINEERING PLASTICS LTD. 216
TABLE 171 SHAILY ENGINEERING PLASTICS LTD.: BUSINESS OVERVIEW 216
11.2.2 BESPAK EUROPE LTD. 217
TABLE 172 BESPAK EUROPE LTD.: BUSINESS OVERVIEW 217
11.2.3 SHL MEDICAL AG 218
TABLE 173 SHL MEDICAL AG: BUSINESS OVERVIEW 218
11.2.4 EMPERRA GMBH 219
TABLE 174 EMPERRA GMBH: BUSINESS OVERVIEW 219
11.2.5 NEMERA FRANCE SAS 220
TABLE 175 NEMERA FRANCE SAS: BUSINESS OVERVIEW 220
11.2.6 COMPANION MEDICAL, INC. 221
TABLE 176 COMPANION MEDICAL, INC.: BUSINESS OVERVIEW 221
11.2.7 JIANGSU DELFU MEDICAL DEVICE CO., LTD. 222
TABLE 177 JIANGSU DELFU MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW 222
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX 223
12.1 DISCUSSION GUIDE 223
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227
12.3 AVAILABLE CUSTOMIZATIONS 229
12.4 RELATED REPORTS 229
12.5 AUTHOR DETAILS 231


お問合せフォーム

    ※レポートのタイトルは自動で入ります。

    お名前(必須)

    会社名(必須)

    部署名

    メールアドレス(必須)

    電話番号

    当ウェブサイトを知った経由を教えてください。

    お問合せ区分(必須)

    お問合せ内容(必須)

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com